v3.26.1
SEGMENT REPORTING (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Segments
The following table is a reconciliation of the significant expense categories to segment net income (loss) regularly provided to the CODM when managing the Company’s single reporting segment:

Three Months Ended
June 30,		Six Months Ended
June 30,

2026

20252026

2025

(in thousands)(in thousands)
License revenue$— $— $— $(70,000)
Program expenses:
Silevertinib (NSCLC) research and development expenses$2,232 $5,518 $5,020 $10,722 
Silevertinib (GBM) research and development expenses2,633 — 4,001 — 
BDTX-4933 research and development expenses— — — 1,018 
Other research programs and development expenses1
— 371 6 933 
Non-program expenses2
3,196 2,997 5,806 6,543 
Personnel-related expenses2,458 2,671 5,470 6,022 
Other segment items3
(614)(996)(1,362)(1,219)
Segment net (income) loss$9,905 $10,561 $18,941 $(45,981)
(1) Includes cross-program consulting expenses; (2) Includes facilities, information technology, legal, intellectual property, and other general and administrative expense; (3) Includes stock-based compensation expense, depreciation, sublease income, investment accretion, interest income, and other (income) expense.